Obexelimab
Based on 1 Customer Validation
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus.
For research use only. We do not sell to patients.
- Purity: 99.99%
- CAS No.: 1690307-05-1
- Molecular Weight:147.24 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
CD19
Obexelimab can induce the expression levels of apoptosis pathway related genes and promote B cell apoptosis[1]. Obexelimab (10 μg/mL, 3 min) inhibits B cell activation and function by suppressing BCR mediated calcium flux and promoting Fc γ RIIb phosphorylation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:B cells isolated from PBMC of healthy and RA donors
-
Concentration:10 μg/mL
-
Incubation Time:3 min
-
Result:Stimulated FcγRIIb phosphorylation in healthy and RA B cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female C.B-17 SCID mice transplanted with PBMCs[2].
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection (i.p.); twice a week
-
Result:Resulted in inhibition of various immune responses in mice, including IgG, IgM, RF, ACPA, and anti-tetanus antibodies.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of Raji cells labelling CD19 (red) with Obexelimab (HY-P99761). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Immobilized CD19 Protein, Human (HEK293, His, HY-P74330) can bind Obexelimab. The EC50 for this effect is 16.38 ng/mL. -
Loaded Obexelimab on AHC2 biosensor, can bind CD19 Protein, Human (HEK293, His, HY-P74330) with an affinity constant of 1.556E-09 M as determined in BLI assay.
Chemical Information
-
CAS No. 1690307-05-1
-
Appearance Liquid
-
Molecular Weight 147.24 kDa
-
Color Colorless to light yellow
-
SMILES
[Obexelimab]
-
Synonyms
XmAb5871
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Boyles JS, et al. A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases. JCI Insight. 2023 Jul 10;8(13):e166137. [Content Brief]
[2]. Chu SY, et al. Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor. Arthritis Rheumatol. 2014 May;66(5):1153-64. [Content Brief]
[3]. Horton HM, et al. Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol. 2011 Apr 1;186(7):4223-33. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)